Searched for
ISRAEL MAKOV
Buy Sun Pharmaceutical Industries, target Rs 655: Gaurav RatnaparkhiBuy Sun Pharmaceutical Industries at a price target of Rs 655 and a stop loss at Rs 588 from the entry point.22 Oct, 2018, 10.27 AM IST- At the helm at Dr. Reddy's, Erez Israeli will have his task cut outIsraeli will replace Abhijit Mukherjee, who retires following his 15-year stint at the company. Mukherjee's tenure as COO was marked with u...02 Apr, 2018, 04.05 PM IST
- Buy Sun Pharmaceutical Industries, target Rs 520: Manas JaiswalBuy Sun Pharmaceutical Industries Ltd. at a price target of Rs 520.0 and a stop loss at Rs 502 from entry point.21 Mar, 2018, 08.43 AM IST
- Buy Sun Pharmaceutical Industries, target Rs 640: Kunal BothraBuy Sun Pharmaceutical Industries Ltd. at a price target of Rs 640.0 and a stop loss at Rs 550 from entry point.12 Feb, 2018, 09.08 AM IST
- Sell Sun Pharmaceutical Industries, target Rs 543.60: ICICI DirectSell Sun Pharmaceutical Industries Ltd. at a price target of Rs 543.6 and a stop loss at Rs 559.4 from entry point.02 Feb, 2018, 10.02 AM IST
- Buy Sun Pharmaceutical Industries, target Rs 634: Sagar DoshiBuy Sun Pharmaceutical Industries Ltd. at a price target of Rs 634.0 and a stop loss at Rs 575 from entry point.31 Jan, 2018, 08.22 AM IST
- Buy Sun Pharmaceutical Industries, target Rs 610: Shrikant ChouhanBuy Sun Pharmaceutical Industries Ltd. at a price target of Rs 610.0 and a stop loss at Rs 565 from entry point.05 Jan, 2018, 08.24 AM IST
- Buy Sun Pharmaceutical Industries, target Rs 530: Shrikant ChouhanBuy Sun Pharmaceutical Industries at a price target of Rs 530 and a stop loss at Rs 498 from entry point.17 Nov, 2017, 09.25 AM IST
- Buy Sun Pharmaceutical Industries, target Rs 585: Shrikant ChouhanBuy Sun Pharmaceutical Industries at a price target of Rs 585 and a stop loss at Rs 553 from entry point.03 Nov, 2017, 08.46 AM IST
- Sell Sun Pharmaceutical Industries target Rs 519: Siddharth BhamreSell Sun Pharmaceutical Industries Ltd. at a price target of Rs 519 and a stop loss at Rs 588 from entry point.11 Jul, 2017, 01.32 PM IST
- Pharma companies should be ready to adapt to changing norms: Israel Makov, chairman of Sun PharmaceuticalIn the past two years, Indian drug makers have come under severe scrutiny from the USFDA for flouting manufacturing practice norms.15 Dec, 2014, 11.24 AM IST
- Sun Pharma chairman calls for more Indo-Israel collaborationIsrael is trying to create such opportunities across the world so that India can tap the knowledge the country has to offer and Israel can ...11 Dec, 2014, 10.50 PM IST
- Brand Ranbaxy to stay: Israel MakovWill reconsider whether it wants to use the Ranbaxy brand in the US - its largest and most lucrative market, and where it has faced a huge ...10 Apr, 2014, 12.12 PM IST
- Sun Pharma chief Israel Makov hopes the worst is over for RanbaxyMakov said Ranbaxy has a serious problem but Sun has proven its ability to remedy any problem that it had encountered in the past.09 Apr, 2014, 08.21 PM IST
- Sun Pharma-Ranbaxy deal: We will guide Ranbaxy, says Dilip ShanghviShanghvi started his entrepreneurial dreams with a loan of Rs 10,000 from his father. It’s that same instinct that’s needed at Ranbaxy now,...09 Apr, 2014, 08.04 AM IST
- I don’t have targets for acquisitions: Dilip ShanghviIf you have targets for acquisitions you end up making compromises in terms of valuations and you buy things because you have a target and ...09 Apr, 2014, 06.22 AM IST
- Sun Pharma Q4 net stands at Rs 820 croreSun Pharmaceutical Industries Ltd today reported a consolidated net profit of Rs 820.21 crore for the fourth quarter ended March 31, 2012.29 May, 2012, 06.35 PM IST
Load More
